Nautilus Biotechnology, Inc.
NAUTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. With a market capitalization of $216.0M, it sits in micro-cap territory. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Market Cap
$216.0M
Beta
0.81
P/E (TTM)
—
P/E (Fwd)
-2.30
EPS (TTM)
$-0.46
EPS (Fwd)
$-0.74
ROE
-33.7%
ROA
-19.8%
Cash
$95.9M
Total Debt
$28.9M
Free CF
-$28.9M
52W Change
131.3%
Annual Financials
Cash vs Debt
Where NAUT stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, NAUT finished 27.98% below its 150-day moving average ($2.43) and 20.09% below its 200-day moving average ($2.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NAUT overbought or oversold?
At the July 15, 2026 close, NAUT's RSI(14) was 26.2, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $95.9M in cash comfortably exceeding the $28.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$28.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -33.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, NAUT has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Nautilus Biotechnology, Inc. and its sector.